Compare COFS & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COFS | ZURA |
|---|---|---|
| Founded | 1898 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 494.9M | 455.4M |
| IPO Year | 1995 | 2021 |
| Metric | COFS | ZURA |
|---|---|---|
| Price | $36.04 | $1.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $39.67 | $8.00 |
| AVG Volume (30 Days) | 68.1K | ★ 6.9M |
| Earning Date | 10-30-2026 | 10-27-2026 |
| Dividend Yield | ★ 3.16% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.71 | N/A |
| Revenue | ★ $227,624,000.00 | N/A |
| Revenue This Year | $7.83 | N/A |
| Revenue Next Year | $5.05 | N/A |
| P/E Ratio | $13.58 | ★ N/A |
| Revenue Growth | ★ 63.64 | N/A |
| 52 Week Low | $26.63 | $0.93 |
| 52 Week High | $38.89 | $7.25 |
| Indicator | COFS | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 56.10 | 25.17 |
| Support Level | $29.94 | $0.93 |
| Resistance Level | $38.89 | $6.05 |
| Average True Range (ATR) | 0.92 | 0.31 |
| MACD | -0.05 | -0.25 |
| Stochastic Oscillator | 32.08 | 2.27 |
ChoiceOne Financial Services Inc is a full-service banking institution. It is engaged in the business of providing personal and business banking solutions, borrowing solutions, and treasury notes and bonds services. The bank's product and services portfolio consist of time, savings and demand deposits, safe deposit services, automated transaction machine services, commercial and consumer loans, commercial lending to business, industry, agricultural, construction, inventory, and real estate categories. Its primary market area is Kent, Muskegon, Newaygo, and Ottawa counties in western Michigan, and Lapeer, Macomb, and St. Clair counties in southeastern Michigan in the communities where the Bank's respective offices are located.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.